Late-stage cancer patients remain highly responsive to immune activation by the selective TLR8 agonist motolimod (VTX-2337)

Clinical Cancer Research

Volumn 21, Issue 24, 2015, Pages 5445-5452

  Dietsch, Gregory N ^a   Randall, Tressa D ^a   Gottardo, Raphael ^b   Northfelt, Donald W ^c   Ramanathan, Ramesh K ^d,e   Cohen, Peter A ^c   Manjarrez, Kristi L ^a   Newkirk, Mona ^a   Bryan, James Kyle ^a   Hershberg, Robert M ^a  

^a VentiRx Pharmaceuticals   (United States)

^b USA   (United States)

^c MAYO CLINIC   (United States)

^d Virginia G Piper Cancer Center   (United States)

^e Translational Genomic Research Institute (TGen)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MOTOLIMOD; TOLL LIKE RECEPTOR 8; ANTINEOPLASTIC AGENT; BENZAZEPINE DERIVATIVE; CYTOKINE; VTX-2337;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BASAL CELL CARCINOMA; BILE DUCT CARCINOMA; CANCER STAGING; CHILL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE REACTION; INNATE IMMUNITY; KIDNEY CANCER; LIVER CANCER; LYMPHOMA; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VERY ELDERLY; ANIMAL; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; LEUKOCYTE; LEUKOCYTE COUNT; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PRECLINICAL STUDY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; BENZAZEPINES; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; LEUKOCYTE COUNT; LEUKOCYTES; MACACA FASCICULARIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 8; TREATMENT OUTCOME;

EID: 84954126066     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0578     Document Type: Article

References (16)

1. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-84.
2. Hornung V, Barchet W, Schlee M, Hartmann G. RNA recognition via TLR7 and TLR8. Handb Exp Pharmacol 2008;71-86.
3. Ghosh TK, Mickelson DJ, Fink J, Solberg JC, Ingle Weld JR, Hook D, et al. Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. comparison with T-cell receptor-induced responses. Cell Immunol 2006; 243:48-57.
4. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005;174:1259-68.
5. Lu H, Dietsch GN, Matthews MA, Yang Y, Ghanekar S, Inokuma M, et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res 2012;18:499-509.
6. Facciabene A, Malykhin A, Fang C, Danet-Desnoyers G, Matthews MA, et al. TLR8 agonist and doxil chemotherapy potently activate human antitumor immune response in a human immune system mouse model. iSBTc Late-Breaking Poster Abstract Book 2010.
7. Nakamura I, Shibata M, Gonda K, Yazawa T, Shimura T, Anazawa T, et al. Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system. Oncol Lett 2013;5:1682-6.
8. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endotheliumFasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014;20:607-15.
9. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulatesCD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol 2004;165:1853-63.
10. Northfelt DW, Ramanathan RK, Cohen PA, Von Hoff DD, Weiss GJ, Dietsch GN, et al. A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma. Clin Cancer Res 2014;20:3683-91.
11. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995;57: 289-300.
12. Philbin VJ, Levy O. Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities. Biochem Soc Trans 2007;35:1485-91.
13. Stephenson RM, Lim CM, Matthews M, Dietsch G, Hershberg R, Ferris RL. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Cancer Immunol Immunother 2013;62: 1347-57.
14. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013;31:51-72.
15. Harris J, Sengar D, Stewart T, Hyslop D. The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer 1976;37(2 Suppl):1058-69.
16. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.